M. Kraus & Co Sells 240 Shares of Bristol-Myers Squibb (NYSE:BMY)

M. Kraus & Co lessened its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 5.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,279 shares of the biopharmaceutical company’s stock after selling 240 shares during the quarter. M. Kraus & Co’s holdings in Bristol-Myers Squibb were worth $232,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BMY. Northwest Financial Advisors bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at $34,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Wetzel Investment Advisors Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Finally, Fairman Group LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $42,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded up $0.89 during mid-day trading on Friday, hitting $41.93. 34,445,182 shares of the stock were exchanged, compared to its average volume of 15,678,345. The firm’s 50-day simple moving average is $43.60 and its 200 day simple moving average is $48.45. Bristol-Myers Squibb has a fifty-two week low of $39.63 and a fifty-two week high of $65.85. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock has a market capitalization of $85.00 billion, a price-to-earnings ratio of -13.53, a price-to-earnings-growth ratio of 13.82 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the company earned $2.05 EPS. The company’s revenue was up 4.7% on a year-over-year basis. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.72%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analysts Set New Price Targets

BMY has been the subject of a number of research analyst reports. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. BMO Capital Markets cut their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, Barclays cut their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $60.00.

Read Our Latest Stock Analysis on Bristol-Myers Squibb

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.